Press releases
- Sarepta Therapeutics to Present at Upcoming Investor Conferences
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
- Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
- Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
- Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
- Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
- Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
- Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
As of last trade Sarepta Therapeutics Inc (AB3A:BER) traded at 119.70, -16.99% below its 52-week high of 144.20, set on May 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 119.70 |
---|---|
High | 119.70 |
Low | 119.70 |
Bid | 119.00 |
Offer | 119.85 |
Previous close | 118.15 |
Average volume | 16.22 |
---|---|
Shares outstanding | 93.86m |
Free float | 89.37m |
P/E (TTM) | -- |
Market cap | 12.22bn USD |
EPS (TTM) | -6.15 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:08 BST.
More ▼